Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
14 November 2018 - 3:50AM
- Company’s novel, broad spectrum influenza
antivirals specifically designed to be effective against all
significant A strains of the influenza virus -
Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the
“Company”), a clinical stage biotechnology company discovering and
developing novel antiviral therapeutics that target the
replication machinery of hepatitis viruses, influenza viruses
and noroviruses, announced today that Sam Lee, Ph.D.,
President of Cocrystal, presented at the 6th ISIRV-AVG Conference,
Advances in Respiratory Virus Therapeutics, being held November
13-15, 2018 in Washington DC, USA.
Dr. Lee’s oral presentation, “Preclinical
characterization of CC-42344, a broad spectrum, potent influenza A
strain PB2 inhibitor for potential triple route (oral, inhalation,
and IV) treatment,” discussed CC-42344, the Company’s lead molecule
currently being evaluated in preclinical IND-enabling studies for
the treatment of influenza. CC-43244 binds to a highly conserved
PB2 site of influenza polymerase complex and exhibits a novel
mechanism of action. To access Dr. Lee’s presentation, please click
here.
“CC-42344 was created using our unique
structure-based technology. It has a favorable safety profile and
pharmacokinetic properties in preclinical testing. Importantly,
CC-42344 has exhibited broad-spectrum activity in cell culture
against seasonal and pandemic influenza strains,” commented Dr.
Lee. “We continue to be encouraged by the data we are seeing and
are evaluating oral, intravenous and inhaled routes of delivery. We
look forward to providing additional updates as we continue to
advance this potentially transformational program for the treatment
of influenza.”
Cocrystal is developing novel, broad spectrum
influenza antivirals that are specifically designed to be effective
against all significant A strains of the influenza virus and to
have a high barrier to resistance due to the way they target the
virus’s replication machinery. Cocrystal’s uniquely developed
molecules target the influenza polymerase, an essential replication
enzyme with several highly essential regions common to influenza
strains, including pandemic strains.
About The International Society for
Influenza and other Respiratory Virus Diseases (ISIRV)
The ISIRV is an independent and international
scientific professional society promoting the prevention,
detection, treatment, and control of influenza and other
respiratory virus diseases. ISIRV was founded in 2005 as the first
scientific society with a fully worldwide remit focused on
influenza and respiratory virus disease. A particular stimulus for
its creation was also the need for an organization to ensure
continuation of the Options for the Control of Influenza
conferences which were growing ever larger. Influenza and acute
respiratory virus disease is a field of public health of major
international importance. Recent epidemiological events - the 2009
pandemic of H1N1 influenza, first identified in Mexico; the
occurrence of human cases of avian influenza A (H7N9) in
China; the emergence of Middle East Respiratory Syndrome
(MERS-CoV); and ongoing outbreaks of virulent avian influenza A
(H5N1) in several countries; continue to highlight the requirement
for international collaboration on respiratory virus research
and development.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical stage biotechnology company
discovering and developing novel antiviral therapeutics that target
the replication machinery of hepatitis C viruses, influenza
viruses, and noroviruses. Cocrystal employs unique structure-based
technologies and Nobel Prize winning expertise to create first- and
best-in-class antiviral drugs. CC-31244 is a broad-spectrum novel
non-nucleoside replication inhibitor of the hepatitis C virus.
Phase 1b studies in HCV-infected patients showed the largest
reduction in viral load of any non-nucleoside inhibitor tested to
date. CC-31244 is now in a Phase 2a clinical trial as part of a
cocktail for the ultra-short therapy of 6 weeks. The Company’s lead
candidate CC-42344 for influenza is effective in animal models
against both the pandemic and seasonal strains of influenza A. In
addition, novel inhibitors effective against both influenza strains
A and B have been identified and are in the preclinical stage.
Several of these have potencies approaching single digit nanomolar.
We continue to identify and develop non-nucleoside polymerase
inhibitors for Norovirus infections using the Company’s proprietary
structure-based drug design technology platform. For further
information about Cocrystal, please visit
www.cocrystalpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including the results of our Phase 2a clinical
trial. The words "believe," "may," "estimate," "continue,"
"anticipate," "intend," "should," "plan," "could," "target,"
"potential," "is likely," "will," "expect" and similar expressions,
as they relate to us, are intended to identify forward-looking
statements. We have based these forward-looking statements largely
on our current expectations and projections about future events.
Some or all of the events anticipated by these forward-looking
statements may not occur. Important factors that could cause actual
results to differ from those in the forward-looking statements
include the evaluation of the results of the Phase 2a study, the
availability of products manufactured by third parties and receipt
of regulatory approvals. Further information on our risk factors is
contained in our filings with the SEC, including our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2018, the
Prospectus Supplement dated April 30, 2018, and our Annual Report
on Form 10-K for the year ended December 31, 2017. Any
forward-looking statement made by us herein speaks only as of the
date on which it is made. Factors or events that could cause our
actual results to differ may emerge from time to time, and it is
not possible for us to predict all of them. We undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise, except as may be required by law.
Investor and Media
Contact:Jenene Thomas Communications, LLC(833)
475-8247COCP@jtcir.com
###
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2024 to May 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From May 2023 to May 2024